ImmunoPrecise Antibodies Ltd. (IPA)
USD 0.43
(-0.46%)
USD 0.43
(-0.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 10.22 Million CAD | 1109.08% |
| 2022 | -1.01 Million CAD | 96.31% |
| 2021 | -27.41 Million CAD | 28.41% |
| 2020 | -38.3 Million CAD | -2111.92% |
| 2019 | 1.9 Million CAD | 174.82% |
| 2018 | -2.54 Million CAD | -226.43% |
| 2017 | 2.01 Million CAD | 178.06% |
| 2016 | -2.57 Million CAD | -656.41% |
| 2015 | -340.88 Thousand CAD | -586.24% |
| 2014 | 70.1 Thousand CAD | -14.86% |
| 2013 | 82.34 Thousand CAD | 130.38% |
| 2012 | 35.74 Thousand CAD | 292.25% |
| 2011 | -18.59 Thousand CAD | 77.62% |
| 2010 | -83.07 Thousand CAD | 23.48% |
| 2009 | -108.55 Thousand CAD | 65.96% |
| 2008 | -318.94 Thousand CAD | -59.92% |
| 2007 | -199.43 Thousand CAD | 44.6% |
| 2006 | -359.97 Thousand CAD | -1105.3% |
| 2005 | -29.86 Thousand CAD | 98.82% |
| 2004 | -2.53 Million CAD | -374.73% |
| 2003 | -534.1 Thousand CAD | -15421.91% |
| 2002 | -3441.00 CAD | 87.14% |
| 2001 | -26.74 Thousand CAD | 65.95% |
| 2000 | -78.54 Thousand CAD | 16.61% |
| 1999 | -94.19 Thousand CAD | 76.91% |
| 1998 | -407.95 Thousand CAD | 53.8% |
| 1997 | -883.06 Thousand CAD | -146.43% |
| 1996 | -358.35 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 12.18 Million CAD | -1688.65% |
| 2023 FY | 10.22 Million CAD | 1109.08% |
| 2023 Q4 | 10.22 Million CAD | 24.86% |
| 2023 Q1 | -18.11 Million CAD | -1688.65% |
| 2023 Q2 | 3.55 Million CAD | 119.63% |
| 2023 Q3 | 8.18 Million CAD | 130.17% |
| 2022 Q2 | -8.37 Million CAD | 53.78% |
| 2022 Q4 | -1.01 Million CAD | 73.68% |
| 2022 Q1 | -18.11 Million CAD | 33.92% |
| 2022 FY | -1.01 Million CAD | 96.31% |
| 2022 Q3 | -3.84 Million CAD | 54.04% |
| 2021 Q2 | -35.43 Million CAD | 5.29% |
| 2021 Q3 | -30.17 Million CAD | 14.84% |
| 2021 Q1 | -37.41 Million CAD | 2.33% |
| 2021 Q4 | -27.41 Million CAD | 9.12% |
| 2021 FY | -27.41 Million CAD | 28.41% |
| 2020 FY | -38.3 Million CAD | -2111.92% |
| 2020 Q1 | -1.03 Million CAD | -154.49% |
| 2020 Q3 | -12.05 Million CAD | 4.15% |
| 2020 Q4 | -38.3 Million CAD | -217.8% |
| 2020 Q2 | -12.57 Million CAD | -1112.13% |
| 2019 Q4 | 1.9 Million CAD | -14.13% |
| 2019 FY | 1.9 Million CAD | 174.82% |
| 2019 Q3 | 2.21 Million CAD | 50.26% |
| 2019 Q1 | -331.23 Thousand CAD | 86.98% |
| 2019 Q2 | 1.47 Million CAD | 545.46% |
| 2018 Q4 | -2.54 Million CAD | 40.39% |
| 2018 Q3 | -4.26 Million CAD | 29.72% |
| 2018 Q1 | 1.73 Million CAD | -14.01% |
| 2018 FY | -2.54 Million CAD | -226.43% |
| 2018 Q2 | -6.07 Million CAD | -450.94% |
| 2017 Q1 | -1.26 Million CAD | 50.75% |
| 2017 FY | 2.01 Million CAD | 178.06% |
| 2017 Q4 | 2.01 Million CAD | 209.5% |
| 2017 Q3 | -1.83 Million CAD | 18.58% |
| 2017 Q2 | -2.25 Million CAD | -77.79% |
| 2016 Q1 | 73.48 Thousand CAD | -1.31% |
| 2016 Q4 | -2.57 Million CAD | 20.19% |
| 2016 Q2 | -463.37 Thousand CAD | -730.61% |
| 2016 Q3 | -3.23 Million CAD | -597.17% |
| 2016 FY | -2.57 Million CAD | -656.41% |
| 2015 Q4 | 74.45 Thousand CAD | 0.78% |
| 2015 Q2 | 73.4 Thousand CAD | 3.03% |
| 2015 Q1 | 71.24 Thousand CAD | -3.04% |
| 2015 FY | -340.88 Thousand CAD | -586.24% |
| 2015 Q3 | 73.87 Thousand CAD | 0.65% |
| 2014 Q2 | 68.86 Thousand CAD | 2.99% |
| 2014 Q3 | 70.1 Thousand CAD | 1.81% |
| 2014 Q4 | 73.48 Thousand CAD | 4.82% |
| 2014 FY | 70.1 Thousand CAD | -14.86% |
| 2014 Q1 | 66.86 Thousand CAD | -43.11% |
| 2013 Q3 | 82.34 Thousand CAD | 226.12% |
| 2013 Q2 | 25.25 Thousand CAD | -69.08% |
| 2013 Q1 | 81.66 Thousand CAD | -6.81% |
| 2013 Q4 | 117.53 Thousand CAD | 42.73% |
| 2013 FY | 82.34 Thousand CAD | 130.38% |
| 2012 FY | 35.74 Thousand CAD | 292.25% |
| 2012 Q4 | 87.62 Thousand CAD | 145.16% |
| 2012 Q3 | 35.74 Thousand CAD | 449.74% |
| 2012 Q2 | -10.22 Thousand CAD | 53.35% |
| 2012 Q1 | -21.91 Thousand CAD | -42.66% |
| 2011 Q4 | -15.35 Thousand CAD | 17.39% |
| 2011 Q2 | -23.62 Thousand CAD | 29.59% |
| 2011 Q1 | -33.55 Thousand CAD | 39.73% |
| 2011 Q3 | -18.59 Thousand CAD | 21.31% |
| 2011 FY | -18.59 Thousand CAD | 77.62% |
| 2010 Q4 | -55.67 Thousand CAD | 32.98% |
| 2010 Q2 | -24.28 Thousand CAD | -52.71% |
| 2010 Q1 | -15.9 Thousand CAD | 73.72% |
| 2010 FY | -83.07 Thousand CAD | 23.48% |
| 2010 Q3 | -83.07 Thousand CAD | -242.02% |
| 2009 Q4 | -60.52 Thousand CAD | 44.24% |
| 2009 Q2 | -104.54 Thousand CAD | 22.95% |
| 2009 Q3 | -108.55 Thousand CAD | -3.84% |
| 2009 FY | -108.55 Thousand CAD | 65.96% |
| 2009 Q1 | -135.68 Thousand CAD | 2.61% |
| 2008 Q1 | -46.42 Thousand CAD | 67.68% |
| 2008 Q2 | -666.45 Thousand CAD | -1335.51% |
| 2008 Q3 | -318.94 Thousand CAD | 52.14% |
| 2008 FY | -318.94 Thousand CAD | -59.92% |
| 2008 Q4 | -139.32 Thousand CAD | 56.32% |
| 2007 Q2 | -260.45 Thousand CAD | 25.09% |
| 2007 Q1 | -347.7 Thousand CAD | -249.35% |
| 2007 FY | -199.43 Thousand CAD | 44.6% |
| 2007 Q4 | -143.66 Thousand CAD | 27.96% |
| 2007 Q3 | -199.43 Thousand CAD | 23.43% |
| 2006 Q4 | -99.52 Thousand CAD | 72.35% |
| 2006 FY | -359.97 Thousand CAD | -1105.3% |
| 2006 Q1 | -1.87 Million CAD | -302.95% |
| 2006 Q3 | -359.97 Thousand CAD | 48.6% |
| 2006 Q2 | -700.32 Thousand CAD | 62.66% |
| 2005 Q4 | -465.47 Thousand CAD | -1458.56% |
| 2005 Q3 | -29.86 Thousand CAD | 97.65% |
| 2005 Q2 | -1.27 Million CAD | 37.53% |
| 2005 Q1 | -2.03 Million CAD | 12.81% |
| 2005 FY | -29.86 Thousand CAD | 98.82% |
| 2004 Q2 | -775.79 Thousand CAD | 28.93% |
| 2004 Q3 | -2.53 Million CAD | -226.84% |
| 2004 FY | -2.53 Million CAD | -374.73% |
| 2004 Q4 | -2.33 Million CAD | 8.03% |
| 2004 Q1 | -1.09 Million CAD | 7.45% |
| 2003 FY | -534.1 Thousand CAD | -15421.91% |
| 2003 Q3 | -534.1 Thousand CAD | -26.5% |
| 2003 Q1 | -21.91 Thousand CAD | 50.68% |
| 2003 Q2 | -422.22 Thousand CAD | -1826.4% |
| 2003 Q4 | -1.17 Million CAD | -120.81% |
| 2002 FY | -3441.00 CAD | 87.14% |
| 2002 Q4 | -44.44 Thousand CAD | -1191.51% |
| 2002 Q2 | -43.25 Thousand CAD | 56.61% |
| 2002 Q1 | -99.67 Thousand CAD | -254.17% |
| 2002 Q3 | -3441.00 CAD | 92.04% |
| 2001 Q4 | -28.14 Thousand CAD | -5.22% |
| 2001 Q1 | -51.49 Thousand CAD | -26.6% |
| 2001 Q2 | -28.41 Thousand CAD | 44.81% |
| 2001 Q3 | -26.74 Thousand CAD | 5.88% |
| 2001 FY | -26.74 Thousand CAD | 65.95% |
| 2000 Q2 | -9433.00 CAD | 52.35% |
| 2000 Q4 | -40.67 Thousand CAD | 48.22% |
| 2000 Q1 | -19.79 Thousand CAD | 59.01% |
| 2000 FY | -78.54 Thousand CAD | 16.61% |
| 2000 Q3 | -78.54 Thousand CAD | -732.7% |
| 1999 FY | -94.19 Thousand CAD | 76.91% |
| 1999 Q4 | -48.29 Thousand CAD | 48.73% |
| 1999 Q3 | -94.19 Thousand CAD | 0.0% |
| 1998 Q3 | -407.95 Thousand CAD | 0.0% |
| 1998 FY | -407.95 Thousand CAD | 53.8% |
| 1997 FY | -883.06 Thousand CAD | -146.43% |
| 1997 Q3 | -883.06 Thousand CAD | 0.0% |
| 1996 FY | -358.35 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 236.764% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 93.781% |
| IO Biotech, Inc. | -140.69 Million USD | 107.265% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 133.559% |
| Organovo Holdings, Inc. | -1.5 Million USD | 778.301% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 488.353% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 960.34% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 167.539% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 118.298% |
| Savara Inc. | 153 Thousand USD | -6581.046% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 144.802% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 133.122% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -46.698% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 426.684% |
| Soligenix, Inc. | -4.95 Million USD | 306.438% |
| Aptose Biosciences Inc. | -8.19 Million USD | 224.737% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 47.966% |
| Century Therapeutics, Inc. | 847 Thousand USD | -1106.848% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 70.17% |
| Precision BioSciences, Inc. | -85.41 Million USD | 111.968% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 105.116% |
| Kura Oncology, Inc. | -20.11 Million USD | 150.81% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 213.792% |
| Dyadic International, Inc. | -6.37 Million USD | 260.267% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 124.977% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 106.631% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 419.737% |
| Autolus Therapeutics plc | -186.59 Million USD | 105.478% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 164.156% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 103.706% |
| GRI Bio, Inc. | -1.79 Million USD | 669.788% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 130.736% |
| IGM Biosciences, Inc. | -72.6 Million USD | 114.079% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 93.228% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 120.178% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 454.325% |
| Opthea Limited | 28.15 Million USD | 63.697% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 124.82% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 67.941% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 119.71% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 160.885% |
| Surrozen, Inc. | -32.66 Million USD | 131.294% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 343.179% |
| Cingulate Inc. | 3.08 Million USD | -231.594% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 46.087% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 90.78% |
| Acelyrin, Inc. | -216.9 Million USD | 104.713% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 123.53% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 170.125% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 103.227% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 113.198% |
| ADMA Biologics, Inc. | 90.06 Million USD | 88.651% |
| PureTech Health plc | -167.19 Million USD | 106.114% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 260.245% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 237.837% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 107.917% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 140.416% |
| Synaptogenix, Inc. | -28.66 Million USD | 135.665% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 1192.094% |
| ChromaDex Corporation | -24.04 Million USD | 142.507% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 219.651% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 240.681% |
| Exelixis, Inc. | -73.05 Million USD | 113.993% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 83.313% |
| Better Therapeutics, Inc. | -860 Thousand USD | 1288.605% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 142.569% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 104.235% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 243.972% |
| Seer, Inc. | -4.24 Million USD | 341.085% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -715.152% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 126.958% |
| Gritstone bio, Inc. | 39.49 Million USD | 74.115% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 112.154% |
| Avid Bioservices, Inc. | 169.72 Million USD | 93.977% |
| Insmed Incorporated | 721.62 Million USD | 98.583% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -290.749% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 390.976% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 83.424% |
| MediWound Ltd. | -5.32 Million USD | 292.071% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 71.734% |
| Fortress Biotech, Inc. | 7.66 Million USD | -33.359% |
| OmniAb, Inc. | 9.2 Million USD | -11.072% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 88.11% |
| Zai Lab Limited | -775 Million USD | 101.319% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 96.998% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 105.29% |
| Veracyte, Inc. | -203.82 Million USD | 105.015% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 212.664% |
| FibroGen, Inc. | 56.76 Million USD | 81.993% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 108.791% |
| ContextLogic Inc. | -232 Million USD | 104.406% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 221.719% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 461.574% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 109.248% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 99.777% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -1527.707% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 405.956% |
| ImmuCell Corporation | 10.99 Million USD | 6.993% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 99.349% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 141.77% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 112.154% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 128.988% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 105.998% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -79.617% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 111.066% |
| Vaxxinity, Inc. | 10.13 Million USD | -0.888% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 98.612% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 194.933% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 396.06% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 167.644% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -145.958% |
| Senti Biosciences, Inc. | 1.74 Million USD | -487.471% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 1515.672% |
| Apollomics, Inc. | -27.39 Million USD | 137.313% |
| 89bio, Inc. | -289.05 Million USD | 103.536% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -138.832% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 541.169% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 125.195% |
| Ardelyx, Inc. | 34.51 Million USD | 70.381% |
| Pluri Inc. | 22.82 Million USD | 55.224% |
| Prothena Corporation plc | -608.34 Million USD | 101.68% |
| Pulmatrix, Inc. | -10.41 Million USD | 198.128% |
| Celularity Inc. | 65.19 Million USD | 84.32% |
| MeiraGTx Holdings plc | -40.3 Million USD | 125.364% |
| Omeros Corporation | 331.17 Million USD | 96.913% |
| Ainos, Inc. | 4.07 Million USD | -150.667% |
| Humacyte, Inc. | -22.48 Million USD | 145.459% |
| Mesoblast Limited | 55.96 Million USD | 81.734% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 141.595% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 133.08% |
| Blueprint Medicines Corporation | 702.83 Million USD | 98.546% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 105.431% |
| Summit Therapeutics Inc. | 34.67 Million USD | 70.52% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 268.624% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 125.531% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 109.176% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 117.053% |
| Cytokinetics, Incorporated | 642.37 Million USD | 98.409% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 275.545% |
| Nutriband Inc. | -251.65 Thousand USD | 4161.878% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 129.96% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.169% |
| Evogene Ltd. | -19.63 Million USD | 152.063% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 121.002% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 210.661% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 99.251% |
| BioLineRx Ltd. | 7.33 Million USD | -39.34% |
| Atai Life Sciences N.V. | -28.55 Million USD | 135.794% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 108.733% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 79.024% |
| MediciNova, Inc. | -50.78 Million USD | 120.129% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 112.971% |
| MiMedx Group, Inc. | -33.9 Million USD | 130.153% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 105.711% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 110.778% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 103.48% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 162.907% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -123.872% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 104.36% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 110.85% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 110.682% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 126.161% |
| Allakos Inc. | -24.97 Million USD | 140.929% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 169.339% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 107.549% |
| BioAtla, Inc. | -109.01 Million USD | 109.377% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 14.575% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 148.21% |
| Precigen, Inc. | -481 Thousand USD | 2225.156% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 1285.724% |
| XOMA Corporation | -29 Million USD | 135.248% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 161.727% |
| Incyte Corporation | -3.17 Billion USD | 100.322% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 213.376% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 108.201% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 155.195% |
| CRISPR Therapeutics AG | -150.84 Million USD | 106.776% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 104.911% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 111.019% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 1289.734% |
| UroGen Pharma Ltd. | 4.39 Million USD | -132.794% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 90.992% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -14104.719% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 145.863% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 105.537% |
| Chimerix, Inc. | -25.51 Million USD | 140.06% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 15.96% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 618.933% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 117.362% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 147.309% |
| Portage Biotech Inc. | -4.98 Million USD | 305.22% |
| OncoCyte Corporation | -6.56 Million USD | 255.752% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -1039.052% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 221.964% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 324.381% |
| Purple Biotech Ltd. | -14.13 Million USD | 172.302% |
| NextCure, Inc. | -6.47 Million USD | 257.82% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 161.238% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 237.427% |
| Generation Bio Co. | 31.44 Million USD | 67.496% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 102.772% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 93.68% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 234.571% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -1288.734% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 120.733% |
| Novavax, Inc. | -298.29 Million USD | 103.427% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 408.175% |
| Curis, Inc. | -23.88 Million USD | 142.793% |
| Daré Bioscience, Inc. | -5.15 Million USD | 298.181% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 264.659% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 211.82% |
| Bicycle Therapeutics plc | -481.46 Million USD | 102.123% |
| BeiGene, Ltd. | -2.25 Billion USD | 100.454% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 17.154% |
| Alector, Inc. | -35.63 Million USD | 128.684% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 105.508% |
| Erasca, Inc. | -37.21 Million USD | 127.467% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 307.427% |
| Aura Biosciences, Inc. | -21.52 Million USD | 147.489% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 22.789% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 213.881% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 893.699% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 158.761% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 97.301% |
| Histogen Inc. | -7.48 Million USD | 236.53% |
| Fortress Biotech, Inc. | 7.66 Million USD | -33.359% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 105.833% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 112.393% |
| Galecto, Inc. | -21.21 Million USD | 148.181% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 98.399% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 104.218% |
| Molecular Templates, Inc. | 707 Thousand USD | -1345.827% |
| PDS Biotechnology Corporation | -32.7 Million USD | 131.251% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 106.159% |
| Amarin Corporation plc | -191.04 Million USD | 105.351% |
| TG Therapeutics, Inc. | 17.86 Million USD | 42.772% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 188.833% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 131.675% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 129.736% |
| Onconetix, Inc. | 5.33 Million USD | -91.731% |
| MacroGenics, Inc. | -66.98 Million USD | 115.26% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 113.238% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 120.241% |
| Adagene Inc. | -87.62 Million USD | 111.665% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 115.08% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 115.498% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 121.072% |
| SciSparc Ltd. | -2.06 Million USD | 595.012% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 185.242% |
| Minerva Neurosciences, Inc. | 41 Million USD | 75.071% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 105.829% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 133.056% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 91.233% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 111.324% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 99.453% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -48.261% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 249.773% |
| 2seventy bio, Inc. | 181.71 Million USD | 94.375% |
| Clene Inc. | 3.34 Million USD | -206.048% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 147.52% |
| GeoVax Labs, Inc. | -6.45 Million USD | 258.417% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 593.733% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 158.199% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 8305.499% |
| Absci Corporation | -72.59 Million USD | 114.08% |
| XBiotech Inc. | -200.02 Million USD | 105.11% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 296.237% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -125.751% |
| Entera Bio Ltd. | -10.62 Million USD | 196.171% |
| Trevena, Inc. | 2.25 Million USD | -352.702% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 108.608% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 143.173% |
| INmune Bio, Inc. | -25.41 Million USD | 140.227% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 139.316% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 119.845% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 448.042% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -42.229% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 210.018% |
| Jaguar Health, Inc. | 29.39 Million USD | 65.221% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 27.406% |
| NexImmune, Inc. | -3.13 Million USD | 426.202% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 109.685% |
| Clearmind Medicine Inc. | -3.94 Million USD | 359.268% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 4273.812% |
| Kronos Bio, Inc. | -36.05 Million USD | 128.352% |
| Innoviva, Inc. | 255.56 Million USD | 96.0% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 97.295% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 137.72% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -8.641% |
| Verastem, Inc. | -37.27 Million USD | 127.421% |
| ProKidney Corp. | -56.23 Million USD | 118.177% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -601.036% |
| Imunon, Inc. | -4.21 Million USD | 342.581% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 118.84% |
| Statera Biopharma, Inc. | 14.41 Million USD | 29.095% |
| ImmunityBio, Inc. | 618.22 Million USD | 98.347% |
| Korro Bio, Inc. | -132.94 Million USD | 107.689% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 97.051% |
| Kineta, Inc. | -4.54 Million USD | 325.105% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 107.624% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 212.544% |
| GT Biopharma, Inc. | -1.02 Million USD | 1101.175% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 103.228% |
| Celularity Inc. | 65.19 Million USD | 84.32% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 422.562% |
| CalciMedica, Inc. | -5.53 Million USD | 284.846% |
| Cibus, Inc. | -8.07 Million USD | 226.541% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 118.38% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 200.078% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 341.712% |
| Kodiak Sciences Inc. | -103.87 Million USD | 109.841% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 130.74% |
| Annexon, Inc. | -193.75 Million USD | 105.276% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -28294.444% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 158.415% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 271.022% |
| Moderna, Inc. | -2.9 Billion USD | 100.352% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 126.8% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 99.03% |
| Vor Biopharma Inc. | 4.3 Million USD | -137.721% |
| Eyenovia, Inc. | 1.25 Million USD | -712.106% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 346.729% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 62.007% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 112.456% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 106.076% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 415.202% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 107.776% |
| Immunocore Holdings plc | -358.59 Million USD | 102.851% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 137.218% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 77.849% |
| Alkermes plc | -166.73 Million USD | 106.131% |
| Arcellx, Inc. | -296.95 Million USD | 103.442% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -358.277% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 42.363% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 113.616% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 149.317% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 45541.209% |
| Moolec Science SA | 117.61 Thousand USD | -8590.994% |
| Biomea Fusion, Inc. | -166.57 Million USD | 106.137% |
| RenovoRx, Inc. | -1.17 Million USD | 971.441% |
| Geron Corporation | 14.76 Million USD | 30.75% |
| Mereo BioPharma Group plc | -51.46 Million USD | 119.86% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 142.526% |
| Royalty Pharma plc | 5.65 Billion USD | 99.819% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 107.228% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 246.25% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 142.977% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 290.607% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 107.264% |
| Humacyte, Inc. | -22.48 Million USD | 145.459% |
| Structure Therapeutics Inc. | -124.33 Million USD | 108.221% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -1288.734% |
| Genelux Corporation | -6.89 Million USD | 248.166% |
| ESSA Pharma Inc. | -33.62 Million USD | 130.403% |
| aTyr Pharma, Inc. | -7.44 Million USD | 237.226% |
| Notable Labs, Ltd. | -9.77 Million USD | 204.562% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 13668.906% |
| Mustang Bio, Inc. | -3.73 Million USD | 373.608% |
| Immunovant, Inc. | -635.22 Million USD | 101.609% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -529.864% |
| Vericel Corporation | 1.27 Million USD | -700.47% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 99.26% |
| Akari Therapeutics, Plc | -3.84 Million USD | 365.852% |
| Acasti Pharma Inc. | -23 Million USD | 144.434% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 403.573% |
| Vaxcyte, Inc. | -368.22 Million USD | 102.776% |
| Orgenesis Inc. | 21.78 Million USD | 53.076% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 111.144% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 145.979% |
| GH Research PLC | -78.07 Million USD | 113.092% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 155.049% |
| PepGen Inc. | -60.67 Million USD | 116.849% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 144.49% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 349.831% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 1285.724% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 343.179% |
| Silo Pharma, Inc. | -3.52 Million USD | 390.043% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -10145.667% |
| Belite Bio, Inc | -87.27 Million USD | 111.713% |
| Pharming Group N.V. | 109.8 Million USD | 90.691% |
| XOMA Corporation | -29 Million USD | 135.248% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 138.344% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 155.195% |
| Bionomics Limited | 227 Million USD | 95.497% |
| Xencor, Inc. | 29.64 Million USD | 65.517% |
| Replimune Group, Inc. | 1.41 Million USD | -623.938% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -0.265% |
| Cassava Sciences, Inc. | -121.13 Million USD | 108.438% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 108.086% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 345.401% |
| Turnstone Biologics Corp. | -14.58 Million USD | 170.091% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 18.296% |
| GeoVax Labs, Inc. | -6.45 Million USD | 258.417% |
| MEI Pharma, Inc. | -3.7 Million USD | 375.897% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 115.459% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 45541.209% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 1188.605% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -9543.396% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 143.029% |
| scPharmaceuticals Inc. | -6.54 Million USD | 256.18% |
| HilleVax, Inc. | -165.48 Million USD | 106.177% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -27.345% |
| Tharimmune, Inc. | -10.93 Million USD | 193.477% |
| Genprex, Inc. | -6.73 Million USD | 251.715% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -14.789% |
| Immunic, Inc. | -45.34 Million USD | 122.545% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 111.556% |
| Aptorum Group Limited | 1.35 Million USD | -653.254% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 106.039% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -14.789% |
| OKYO Pharma Limited | -826.84 Thousand USD | 1336.261% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 1417.248% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -762.616% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -461.126% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 94.839% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 282.202% |
| bluebird bio, Inc. | 108.57 Million USD | 90.585% |
| DBV Technologies S.A. | -126.98 Million USD | 108.05% |
| Compugen Ltd. | -12.9 Million USD | 179.216% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 893.699% |
| Peak Bio, Inc. | 10.34 Million USD | 1.143% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 198.744% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 194.056% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 250.257% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 135.405% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 3712.014% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 132.584% |
| Benitec Biopharma Inc. | -50.58 Million USD | 120.209% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 109.797% |
| Adicet Bio, Inc. | -138.78 Million USD | 107.365% |
| Prime Medicine, Inc. | -27.94 Million USD | 136.584% |
| Aditxt, Inc. | 18.12 Million USD | 43.59% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 40.838% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 345.401% |
| Quantum-Si incorporated | -118.55 Million USD | 108.622% |
| GlycoMimetics, Inc. | -40.98 Million USD | 124.941% |
| PolyPid Ltd. | 6.17 Million USD | -65.673% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 86.209% |
| Invivyd, Inc. | -198.47 Million USD | 105.15% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 526.327% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 63.221% |
| CorMedix Inc. | -43.05 Million USD | 123.743% |
| Instil Bio, Inc. | 75.35 Million USD | 86.435% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 102.97% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 94.247% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -104.358% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 114.44% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 503.553% |
| AbCellera Biologics Inc. | -55.94 Million USD | 118.273% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 109.081% |
| Surrozen, Inc. | -32.66 Million USD | 131.294% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -91.531% |
| Verona Pharma plc | -220.44 Million USD | 104.637% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 112.887% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 107.845% |
| Evaxion Biotech A/S | 5.28 Million USD | -93.348% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 107.787% |
| Shattuck Labs, Inc. | -121.42 Million USD | 108.418% |
| AlloVir, Inc. | -62.69 Million USD | 116.305% |
| BioVie Inc. | -17.73 Million USD | 157.646% |
| Codexis, Inc. | -43.27 Million USD | 123.623% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 692.923% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 960.34% |
| Agenus Inc. | 274.13 Million USD | 96.271% |
| Virax Biolabs Group Limited | -3.36 Million USD | 403.779% |
| Lantern Pharma Inc. | -21.7 Million USD | 147.099% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 112.5% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -123.676% |
| Immix Biopharma, Inc. | -17.5 Million USD | 158.379% |
| Celcuity Inc. | 6.78 Million USD | -50.689% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 152.404% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 126.62% |
| IN8bio, Inc. | -16.38 Million USD | 162.371% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 673.303% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 132.912% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 87.773% |
| Liquidia Corporation | -80.17 Million USD | 112.749% |
| Quantum-Si incorporated | -118.55 Million USD | 108.622% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 162.907% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 107.421% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 274.437% |
| United Therapeutics Corporation | -507.7 Million USD | 102.013% |
| Solid Biosciences Inc. | -47.75 Million USD | 121.407% |
| Immuneering Corporation | -54.94 Million USD | 118.605% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 503.553% |
| uniQure N.V. | -102.95 Million USD | 109.929% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 130.746% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 546.77% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 75.038% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 173.773% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 140.496% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 428.011% |
| Cue Biopharma, Inc. | -33.81 Million USD | 130.226% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 153.446% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 114.459% |
| Zura Bio Limited | -99.8 Million USD | 110.242% |
| Forte Biosciences, Inc. | -11.96 Million USD | 185.461% |
| Elevation Oncology, Inc. | -19.11 Million USD | 153.468% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 415.202% |
| Immunome, Inc. | -97.02 Million USD | 110.535% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 145.441% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 114.248% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 35.704% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 105.511% |
| Altimmune, Inc. | -134.48 Million USD | 107.601% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 73.111% |
| Rallybio Corporation | -24.1 Million USD | 142.411% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 333.753% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 107.759% |
| Moolec Science SA | 117.61 Thousand USD | -8590.994% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 430.36% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 829.622% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 107.285% |
| NeurAxis, Inc. | 145.7 Thousand USD | -6915.786% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 71.609% |
| Lumos Pharma, Inc. | -28.49 Million USD | 135.875% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 114.248% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 1658.873% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 47.966% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 149.206% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -601.036% |
| Nutriband Inc. | -251.65 Thousand USD | 4161.878% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 237.392% |
| argenx SE | -2.02 Billion USD | 100.504% |
| Neurogene Inc. | -131.95 Million USD | 107.747% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 53.144% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 308.23% |
| CervoMed Inc. | -7.79 Million USD | 231.172% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 102.71% |
| Sesen Bio, Inc. | -112.55 Million USD | 109.082% |
| AnaptysBio, Inc. | -18.15 Million USD | 156.316% |
| Design Therapeutics, Inc. | -18.15 Million USD | 156.32% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 114.524% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 8.992% |
| Achilles Therapeutics plc | -126.92 Million USD | 108.054% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 502.758% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 177.61% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 96.995% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 56.933% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 102.284% |
| Palisade Bio, Inc. | -12.06 Million USD | 184.738% |
| Beam Therapeutics Inc. | -262.72 Million USD | 103.891% |
| AEON Biopharma, Inc. | -4.88 Million USD | 309.467% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 110.236% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 535.388% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 126.193% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 112.274% |
| Athira Pharma, Inc. | -88.99 Million USD | 111.486% |
| Vaccinex, Inc. | -1.28 Million USD | 893.634% |
| HCW Biologics Inc. | 2.85 Million USD | -257.828% |
| XOMA Corporation | -29 Million USD | 135.248% |
| Nektar Therapeutics | 210.24 Million USD | 95.138% |
| Arvinas, Inc. | -313.8 Million USD | 103.257% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -529.864% |
| Merus N.V. | -192.88 Million USD | 105.3% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 82.959% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 247.334% |
| Rezolute, Inc. | -68.16 Million USD | 114.995% |
| Clene Inc. | 3.34 Million USD | -206.048% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 177.516% |
| BeyondSpring Inc. | -13.75 Million USD | 174.315% |
| Synlogic, Inc. | -6.68 Million USD | 252.909% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -801.411% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 220.899% |
| Peak Bio, Inc. | 10.34 Million USD | 1.143% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 112.402% |
| Krystal Biotech, Inc. | -350.23 Million USD | 102.919% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 91.765% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 106.049% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 423.774% |
| MannKind Corporation | 143.89 Million USD | 92.896% |
| Ikena Oncology, Inc. | -109.15 Million USD | 109.365% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 235.015% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 130.882% |
| Gossamer Bio, Inc. | 180.35 Million USD | 94.332% |
| CohBar, Inc. | -5.93 Million USD | 272.356% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 134.362% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -123.872% |
| Legend Biotech Corporation | -949.39 Million USD | 101.077% |
| Mural Oncology plc | -255.84 Million USD | 103.995% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 68.269% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 316.998% |
| Disc Medicine, Inc. | -358.28 Million USD | 102.853% |
| Champions Oncology, Inc. | 4.81 Million USD | -112.427% |
| REGENXBIO Inc. | 54.76 Million USD | 81.336% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 3901.314% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 106.768% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 213.426% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 112.669% |
| Vaxart, Inc. | -8.24 Million USD | 224.038% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 120.371% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 108.038% |
| Cellectis S.A. | -43.85 Million USD | 123.309% |
| Longeveron Inc. | -2.9 Million USD | 451.513% |
| Repare Therapeutics Inc. | -107.85 Million USD | 109.477% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 98.944% |
| Inozyme Pharma, Inc. | 12 Million USD | 14.845% |
| Revolution Medicines, Inc. | -608.2 Million USD | 101.681% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 931.057% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 103.856% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 106.811% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 165.329% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 1481.351% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.107% |
| Denali Therapeutics Inc. | -74.86 Million USD | 113.654% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 185.242% |
| Veru Inc. | 4.77 Million USD | -113.851% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 190.895% |
| Cingulate Inc. | 3.08 Million USD | -231.594% |
| Passage Bio, Inc. | 4.58 Million USD | -122.944% |
| Context Therapeutics Inc. | -14.44 Million USD | 170.741% |
| Exicure, Inc. | 5.84 Million USD | -74.765% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 104.437% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 125.833% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 101.681% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 34.854% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 117.378% |
| Nuvalent, Inc. | -335.38 Million USD | 103.048% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -489.388% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 113.724% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 214.983% |
| OmniAb, Inc. | 9.2 Million USD | -11.072% |
| Anew Medical, Inc. | 1.43 Million USD | -613.595% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 37.601% |
| Lipocine Inc. | -4.75 Million USD | 314.992% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 109.307% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 32.887% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 120.178% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 58.935% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 252.09% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 115.529% |
| Ocugen, Inc. | -32.52 Million USD | 131.432% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 111.945% |
| Q32 Bio Inc. | -37.94 Million USD | 126.937% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 1727.707% |
| Alumis Inc. Common Stock | -13.52 Million USD | 175.556% |
| Equillium, Inc. | -22.39 Million USD | 145.65% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 139.98% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 131.33% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 4223.187% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 92.374% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -219.637% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -3012.279% |
| Dominari Holdings Inc. | 195 Thousand USD | -5142.051% |
| Edesa Biotech, Inc. | -5.26 Million USD | 294.08% |
| vTv Therapeutics Inc. | -8.91 Million USD | 214.635% |
| Bio-Techne Corporation | 267.74 Million USD | 96.182% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 163.064% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 108.656% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 221.647% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 180.8% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 104.17% |
| Nkarta, Inc. | 57.29 Million USD | 82.16% |
| BioCardia, Inc. | 212 Thousand USD | -4721.698% |
| Iterum Therapeutics plc | 13.43 Million USD | 23.932% |